Form 8-K uniQure N.V. For: Jun 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'
June 17, 2026 1:27 PM EDTMizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).
The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More
uniQure BV (QURE) PT Raised to $71 at Stifel
June 17, 2026 9:31 AM EDTStifel analyst Paul Matteis raised the price target on uniQure BV (NASDAQ: QURE) to $71.00 (from $28.00) while maintaining a Buy rating.
The analyst comments "We're reiterating our Buy rating on QURE and raising our TP to $71, on the back of a positive and welcome surprise around FDA's ~180 on the regulatory path for AMT-130 (LINK). Bottom line: we now model a slightly greater than 50%... More
